137 related articles for article (PubMed ID: 17507218)
21. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
[TBL] [Abstract][Full Text] [Related]
22. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
Knotkova H; Pappagallo M; Szallasi A
Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
[TBL] [Abstract][Full Text] [Related]
23. Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.
Voight EA; Gomtsyan AR; Daanen JF; Perner RJ; Schmidt RG; Bayburt EK; DiDomenico S; McDonald HA; Puttfarcken PS; Chen J; Neelands TR; Bianchi BR; Han P; Reilly RM; Franklin PH; Segreti JA; Nelson RA; Su Z; King AJ; Polakowski JS; Baker SJ; Gauvin DM; Lewis LR; Mikusa JP; Joshi SK; Faltynek CR; Kym PR; Kort ME
J Med Chem; 2014 Sep; 57(17):7412-24. PubMed ID: 25100568
[TBL] [Abstract][Full Text] [Related]
24. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.
Culshaw AJ; Bevan S; Christiansen M; Copp P; Davis A; Davis C; Dyson A; Dziadulewicz EK; Edwards L; Eggelte H; Fox A; Gentry C; Groarke A; Hallett A; Hart TW; Hughes GA; Knights S; Kotsonis P; Lee W; Lyothier I; McBryde A; McIntyre P; Paloumbis G; Panesar M; Patel S; Seiler MP; Yaqoob M; Zimmermann K
J Med Chem; 2006 Jan; 49(2):471-4. PubMed ID: 16420034
[TBL] [Abstract][Full Text] [Related]
25. TRPing the switch on pain: an introduction to the chemistry and biology of capsaicin and TRPV1.
Conway SJ
Chem Soc Rev; 2008 Aug; 37(8):1530-45. PubMed ID: 18648679
[TBL] [Abstract][Full Text] [Related]
26. TRPV1 antagonists: the challenges for therapeutic targeting.
Khairatkar-Joshi N; Szallasi A
Trends Mol Med; 2009 Jan; 15(1):14-22. PubMed ID: 19097938
[TBL] [Abstract][Full Text] [Related]
27. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.
Szallasi A; Cortright DN; Blum CA; Eid SR
Nat Rev Drug Discov; 2007 May; 6(5):357-72. PubMed ID: 17464295
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of a TRPV1 receptor antagonist.
Yu S; Haight A; Kotecki B; Wang L; Lukin K; Hill DR
J Org Chem; 2009 Dec; 74(24):9539-42. PubMed ID: 19928811
[TBL] [Abstract][Full Text] [Related]
29. Heteroaryl beta-tetralin ureas as novel antagonists of human TRPV1.
Jetter MC; Youngman MA; McNally JJ; McDonnell ME; Zhang SP; Dubin AE; Nasser N; Codd EE; Flores CM; Dax SL
Bioorg Med Chem Lett; 2007 Nov; 17(22):6160-3. PubMed ID: 17892935
[TBL] [Abstract][Full Text] [Related]
30. Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists.
Stec MM; Bo Y; Chakrabarti PP; Liao L; Ncube M; Tamayo N; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2008 Sep; 18(18):5118-22. PubMed ID: 18722118
[TBL] [Abstract][Full Text] [Related]
31. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development.
Rami HK; Thompson M; Stemp G; Fell S; Jerman JC; Stevens AJ; Smart D; Sargent B; Sanderson D; Randall AD; Gunthorpe MJ; Davis JB
Bioorg Med Chem Lett; 2006 Jun; 16(12):3287-91. PubMed ID: 16580202
[TBL] [Abstract][Full Text] [Related]
32. Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
Biswas K; Li A; Chen JJ; D'Amico DC; Fotsch C; Han N; Human J; Liu Q; Norman MH; Riahi B; Yuan C; Suzuki H; Mareska DA; Zhan J; Clarke DE; Toro A; Groneberg RD; Burgess LE; Lester-Zeiner D; Biddlecome G; Manning BH; Arik L; Dong H; Huang M; Kamassah A; Loeloff R; Sun H; Hsieh FY; Kumar G; Ng GY; Hungate RW; Askew BC; Johnson E
J Med Chem; 2007 May; 50(9):2200-12. PubMed ID: 17408249
[TBL] [Abstract][Full Text] [Related]
33. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
[TBL] [Abstract][Full Text] [Related]
35. N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.
Westaway SM; Chung YK; Davis JB; Holland V; Jerman JC; Medhurst SJ; Rami HK; Stemp G; Stevens AJ; Thompson M; Winborn KY; Wright J
Bioorg Med Chem Lett; 2006 Sep; 16(17):4533-6. PubMed ID: 16806913
[TBL] [Abstract][Full Text] [Related]
36. Analysis of structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists.
Lee J; Jin MK; Kang SU; Kim SY; Lee J; Shin M; Hwang J; Cho S; Choi YS; Choi HK; Kim SE; Suh YG; Lee YS; Kim YH; Ha HJ; Toth A; Pearce LV; Tran R; Szabo T; Welter JD; Lundberg DJ; Wang Y; Lazar J; Pavlyukovets VA; Morgan MA; Blumberg PM
Bioorg Med Chem Lett; 2005 Sep; 15(18):4143-50. PubMed ID: 15993063
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of benzamide derivatives as TRPV1 antagonists.
Shishido Y; Jinno M; Ikeda T; Ito F; Sudo M; Makita N; Ohta A; Iki-Taki A; Ohmi T; Kanai Y; Tamura T; Shimojo M
Bioorg Med Chem Lett; 2008 Feb; 18(3):1072-8. PubMed ID: 18155908
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
Quintanar-Audelo M; Fernández-Carvajal A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Albericio F
J Med Chem; 2007 Nov; 50(24):6133-43. PubMed ID: 17985859
[TBL] [Abstract][Full Text] [Related]
39. 6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists.
Sun W; Kim HS; Lee S; Jung A; Kim SE; Ann J; Yoon S; Choi S; Lee JH; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Schiene K; Stockhausen H; Christoph T; Frormann S; Lee J
Bioorg Med Chem Lett; 2015 Feb; 25(4):803-6. PubMed ID: 25597011
[TBL] [Abstract][Full Text] [Related]
40. Analysis of structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as TRPV1 antagonists.
Lee J; Kang SU; Kil MJ; Shin M; Lim JO; Choi HK; Jin MK; Kim SY; Kim SE; Lee YS; Min KH; Kim YH; Ha HJ; Tran R; Welter JD; Wang Y; Szabo T; Pearce LV; Lundberg DJ; Toth A; Pavlyukovets VA; Morgan MA; Blumberg PM
Bioorg Med Chem Lett; 2005 Sep; 15(18):4136-42. PubMed ID: 16005215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
